ArticleSurgical case reports2026
Conversion Surgery for Alpha-Fetoprotein-Producing Esophagogastric Junction Cancer with Multiple Liver Metastases and Portal Vein Tumor Thrombus after Nivolumab Combination Chemotherapy: A Case Report and Literature Review.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular pathogenesis and novel therapeutic avenues in alpha-fetoprotein-producing gastric cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlpha-fetoprotein-producing gastric cancer (AFPGC) is a rare subtype of gastric cancer associated with poor prognosis due to early liver metastasis. There have been limited reports on conversion surgery following nivolumab combination chemotherapy in cases of AFPGC with liver metastasis. Here, we present a case of alpha-fetoprotein-producing esophagogastric junction cancer (AFP-EGJC) successfully treated with this treatment. CASE PRESENTATION: The patient was a 31-year-old man. After liver tumors were incidentally detected, he was diagnosed with esophagogastric junction cancer (cT3N1M1) with multiple liver metastases and portal vein tumor thrombus. Combination therapy with S-1 (tegafur/gimeracil/oteracil), oxaliplatin, and nivolumab was initiated. The response was remarkable, with the rapid disappearance of liver metastases. Serum AFP was also abnormally high at 691.9 ng/mL, but it quickly normalized after the start of treatment. Fifteen months later, the patient was diagnosed with progressive disease, and the regimen was switched to nab-paclitaxel and ramucirumab therapy. However, there was no recurrence of liver metastases, and only the primary tumor was poorly controlled. Therefore, a laparoscopic proximal gastrectomy was performed 22 months after the initial treatment. The postoperative diagnosis was ypT2 (MP) N0M0, ypStage IB. The patient remains alive and recurrence-free 12 months after surgery, without adjuvant chemotherapy.
conclusionsConversion surgery after nivolumab combination chemotherapy may be feasible in selected patients with AFP-EGJC with liver metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.